Clinical Trials – September 9, 2026
Novo Nordisk’s semaglutide moves obesity below threshold in nearly half of children in phase 3 trial
In the phase 3 STEP Young trial, 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, compared with none of those on placebo.